Last €3.48 EUR
Change Today 0.00 / 0.00%
Volume 0.0
RN3 On Other Exchanges
As of 3:23 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

arena pharmaceuticals inc (RN3) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/14/14 - €5.89
52 Week Low
10/14/14 - €2.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

arena pharmaceuticals inc (RN3) Related Businessweek News

View More BusinessWeek News

arena pharmaceuticals inc (RN3) Details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. Its products under development include APD811, an agonist of the prostacyclin receptor, which has completed single- and multiple-ascending dose Phase I trials for the treatment of pulmonary arterial hypertension; and temanogrel, an inverse agonist of the serotonin 2A receptor for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials. The company’s products under development also comprise APD334, an agonist of the sphingosine 1-phosphate subtype 1 receptor for the treatment of conditions related to autoimmune diseases, which has completed Phase I single-ascending dose trial; and APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. It also manufactures drug products under a manufacturing services agreement for Siegfried AG. The company was founded in 1997 and is based in San Diego, California.

310 Employees
Last Reported Date: 03/3/14
Founded in 1997

arena pharmaceuticals inc (RN3) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $725.0K
Co-Founder, Executive Vice President, Chief S...
Total Annual Compensation: $420.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $360.0K
Executive Vice President, General Counsel and...
Total Annual Compensation: $395.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2013.

arena pharmaceuticals inc (RN3) Key Developments

Eisai Inc. and Arena Pharmaceuticals, Inc. Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ(R) (lorcaserin HCl) CIV in Postgraduate Medicine

Eisai Inc. and Arena Pharmaceuticals, Inc. announced that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase 3 clinical trials of BELVIQ(R) (lorcaserin HCl). In the pooled analysis, BELVIQ 10 mg twice daily, as compared to placebo and both in conjunction with diet and exercise, was associated with statistically weight loss and clinically relevant improvements in cardiometabolic parameters. BELVIQ is a serotonin 2C receptor agonist approved in the United States as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m(2) or greater (obese), or BMI of 27 kg/m(2) or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes the risk of heart problems or stroke, or death due to heart problems or stroke. The BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) and BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) trials were conducted in overweight and obese adults without diabetes. The pooled, modified-intent-to-treat results show that a statistically significantly greater number of patients taking BELVIQ lost greater than or equal to 5% and greater than or equal to 10% of body weight compared to placebo (47.1% vs. 22.6% and 22.4% vs. 8.7%, respectively) after one year of treatment. The mean percent weight loss for patients taking BELVIQ was also statistically significantly greater than placebo (-5.8% vs. -2.5%). Mean percent weight loss for those completing one year of treatment was -8.0% for BELVIQ and -3.7% for placebo, respectively. Echocardiograms were conducted on all patients as part of the primary safety endpoint of the trials. There was no apparent increased risk of cardiac valvulopathy associated with use in the combined dataset. The rates of FDA-defined valvulopathy were 2.3% and 2.2% for patients taking BELVIQ or placebo, respectively. Additionally, the data showed that after one year, there were statistically significant improvements in lipid parameters, including total cholesterol, triglyceride levels and HDL cholesterol. Changes in glycemic indicators demonstrated a decrease of 0.11% in HbA1c for BELVIQ treated patients compared to a decrease of 0.05% for placebo treated patients. Mean decreases in both systolic and diastolic blood pressure were also seen and statistically significant for BELVIQ versus placebo. The most common adverse events in the pooled analysis included headache, upper respiratory tract infection and nasopharynigtis. Discontinuation rates for adverse events were 8.6% for patients taking BELVIQ and 6.8% for patients taking placebo, and the overall rates for serious adverse events were similar (2.7% and 2.3%, respectively).

US Food and Drug Administration Grants Orphan Drug Status to Arena Pharmaceuticals, Inc.'s APD811

Arena Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.

Arena Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 11:30 AM

Arena Pharmaceuticals, Inc. Presents at The 21st Annual NewsMakers in the Biotech Industry 2014, Sep-26-2014 11:30 AM. Venue: Millennium Broadway Hotel & Conference Center, 145 West 44th Street, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RN3:GR €3.48 EUR 0.00

RN3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $5.94 USD -0.03
Array BioPharma Inc $3.56 USD -0.31
Progenics Pharmaceuticals Inc $4.84 USD -0.02
Rigel Pharmaceuticals Inc $1.98 USD +0.02
Spectrum Pharmaceuticals Inc $7.56 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation RN3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.9x
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARENA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at